Summary Cyclin E is a GI cyclin which has been proposed to be one of the key regulators of the important GI/S transition, and could consequently be a potential deregulated molecule in tumours. Recently, it has been observed that cyclin E is overexpressed in a variety of malignancies including breast cancer and that several isoforms of the protein exists. In this study we have characterised the cyclin E expression in 114 tumour specimens from patients with primary breast cancer using Western blotting. Various expression of cyclin E was observed among tumours and a group of 27 patients out of 100 patients with stage I-III disease, identified as having tumours with high cycin E levels, had a significantly increased risk of death and relapse from breast cancer (P=0.0002 and P=0.015 respectively). Even in the subgroup of axillary node-negative patients the cyclin E level was of prognostic importance. There was also a strong association between cyclin E expression and oestrogen receptor status (P<0.00001), and tumours with high cyclin E expression were in general oestrogen receptor negative, suggesting a potential role for cyclin E in mechanisms responsible for oestrogenindependent tumour growth.
From being considered a disease with a long locoregional stage, breast cancer is now recognised to disseminate early during its course, which, in terms of therapy necessitates consideration of the disease as potentially systemic at time of diagnosis. To this end metastases to axillary lymph nodes, tumour size and grade, oestrogen and progesterone receptor status and tumour proliferation markers, have been used to direct adjuvant therapy (Sigurdsson et al., 1990) . During recent years several biological parameters, such as cathepsin D level in tumour tissue (Tandon et al., 1990) and gene amplification of the proto-oncogene c-erbB2 (neu) (Slamon et al., 1989) , have been under evaluation for their capacity to add new prognostic information, but a marker, or a combination thereof, which can clearly predict whether a patient will experience recurrence has still to be defined. Such ideal prognostic factors would probably be central in the disease pathogenesis, and their identification could most likely give new insight into breast cancer oncogenesis.
Proliferation of normal cells is characterised by rigorous control mechanisms surveying the orderly events leading to DNA replication and mitosis, only allowing further advance in the cell cycle if the previous stages have been executed properly. In tumour cells deficiences in these control mechanisms are important for initiating and exaggerating the malignant phenotype (Hunter and Pines, 1994; Hartwell and Kastan 1994) . The ultimate molecules controlling the cell cycle transitions are a family of protein kinases, the cyclin-dependent kinases (cdks), which are regulated by multiple mechanisms: the accumulation and binding of cyclins, the displacement of inhibitors (such as p16, p21 and p27) and phosphorylation of the cdks by a cdkactivating kinase (Draetta, 1994; Dulic et al., 1992; Xiong et al., 1993; Tassan et al., 1994) . Two cyclins, Dl and E, are key regulators in the G, phase, cyclin E being a candidate for controlling the GI/S transition (Koff et al., 1992) and cyclin Dl of importance in emerging from quiescence and for traversing the GI phase in response to mitogenic signals (Matsushime et al., 1991) . The above-mentioned catalytic and regulatory molecules are potential targets for tumorigenesis because of their critical position in the cell cycle (Hunter and Pines, 1994) . The cdk4 gene has been shown to be amplified in glioma cell lines (He et al., 1994) and the p16 gene is mutated and inactivated in several cell lines and lymphomas having the property of a tumour-suppressor gene (Okamoto et al., 1994; Otsuki et al., 1995) . Cyclin DI was originally identified as a putative proto-oncogene clonally rearranged in a subset of thyroid adenomas by a chromosomal inversion placing the cyclin DI gene in close proximity to the enhancer of the parathyroid hormone gene leading to an overexpression of the cyclin gene product (Motokura et al., 1991) . Cyclin Dl gene rearrangements have also been implicated in mantle cell lymphomas, in head and neck, lung and bladder cancers (Williams et al., 1993; Motokura and Arnold, 1993) and gene amplification of the region lql3 encompassing the cyclin DI gene is found in 15-20% of patients with breast cancer and has been associated with an unfavourable prognosis (Theillet et al., 1990; Lammie et al., 1991; Schuuring et al., 1992) . Transgenic mice overexpressing cyclin Dl develop mammary hyperplasia and adenocarcinoma (Wang et al., 1994) , placing cyclin Dl as an oncogene central in the tumorigenesis of a substantial portion of prevalent cancers.
Evidence for a role of cyclin E in oncogenesis is more circumstantial than for cyclin DI, but deregulation of the gene with overexpression of the protein has been described in various malignancies, including breast cancer (Buckley et al., 1993; Leach et al., 1993; Keyomarsi and Pardee, 1993) . These alterations seem to be specific for tumour cells and may represent a true tumour-associated abnormality. In a limited study on breast cancer specimens, overexpression of cyclin E protein seemed to correlate with tumour aggressiveness as determined by tumour stage and grade, suggesting a potential role for cyclin E as a prognostic marker for breast cancer (Keyomarsi et al., 1994) . However, there are no studies where the potential prognostic importance of cyclin E overexpression has been studied in a larger population of patients.
To gain further insight into the role of cyclin E in breast cancer, we have analysed an archival material of 114 tumour specimens from patients with stage I -IV disease for the expression of cyclin E by Western blotting, correlated the findings with established prognostic factors and evaluated the prognostic significance.
Materials and methods

Patient data
The patient material in this study represents consecutively treated women with primary breast cancer operated on at Umea University Hospital during 1988-1991. Patients to be included had a thorough clinical examination, bilateral mammography, blood tests including liver parameters and a chest radiograph. Of the 114 patients enrolled in the study, 14 patients were omitted from prognostic considerations because of previously or newly diagnosed cancer in the opposite breast (five patients), because of distant metastases at the time of diagnosis (eight patients) or both (one patient). Patients with distant metastases (stage IV) were treated individually, others (stage I-III) were treated with curative intent according to the guidelines recommended by the North Swedish Breast Cancer Group. Briefly, local treatment consisted of either mastectomy or a segmental resection followed by radiation therapy to the remaining breast tissue. Axillary dissection with histopathological examination was performed in 101 patients, and if metastases were detected, adjuvant therapy was given in the form of tamoxifen to postmenopausal and chemotherapy or radiological castration treatment to premenopausal patients. of the BL-42 cell line standard. These normalised optical densities from tumour specimens, hereafter denoted 'relative cyclin E concentrations', were used as numerical variables in the subsequent statistical analysis. The ECL detection system gives accurate and reliable measurements of protein concentrations within one order of magnitude (Kornblau et al., 1994) . To extend this range and ensure that the protein determinations were performed in the linear range of the film, three BL-42 protein standards diluted 1:1, 1:2 and 1:10, were included on each gel and the films exposed for various times. Comparisons between tumour samples and protein standards were performed by using that film in which the optical density between one of the protein standards and the tumour sample did not differ by more than a factor of ten.
Oestrogen and progesterone receptor measurement Receptor content in tumour specimens was determined as part of the routine clinical evaluation of the patients at the time of diagnosis. Briefly, tumour tissue to be analysed was selected by a pathologist, pulverised to homogeneity in liquid nitrogen and suspended in a buffer. The homogenate was centrifuged, the supernatant analysed for oestrogen and progesterone receptor content by an enzyme immunoassaybased system (Abbott Lab., IL, USA) and the pelleted fraction analysed for DNA content by the method of Burton, (1968) . Receptor concentration was thereafter expressed as fmol receptor per gg DNA, and tumours with a value lower than 0.1 were considered receptor negative, those with a value equal to or higher than 0.1 as receptor positive.
Tumour DNA ploidy evaluation DNA ploidy evaluation was performed using flow cytometry on deparaffinised tumour tissue sections as described previously (Arnelov et al., 1990) . DNA histograms were classified as diploid/near-diploid when only one major Go/GQ peak was detected, and as aneuploid when additional peaks were identified.
Statistical methods
Associations between cyclin E levels and other parameters were calculated using contingency tables and applying the X2 test or Fisher's exact test. The Kaplan-Meier method was used in calculating survival curves, and comparison between groups was performed with the log-rank test. Survival was defined as the time elapsed from diagnosis to the appearance of an event, considering either death owing to breast cancer (disease-specific survival) or the occurrence of clinically confirmed local, regional or distant relapse (relapse-free survival). If no event occurred, the patient was censored at the time of latest medical check-up, at the time of occurrence of other malignancy or at the time of death caused by intercurrent disease. Comparison of intervals from diagnosis to occurrence of an event between two groups of patients was performed using the Mann-Whitney U-test. Multivariate analysis was performed with Cox's proportional hazards model for censored data. All calculations were performed in SPSS version 6.0 (SPSS, IL, USA). Figure  3 . A similar association as presented for the oestrogen receptor existed between cyclin E levels and progesterone receptor status (P<0.00001). Aneuploid tumours tended to have higher cyclin E levels (20 of 56 tumours or 35.7%) than diploid tumours (10 of 48 or 20.8%), although the difference did not reach statistical significance (P= 0.095). No significant relationship was found between cyclin E levels and lymph node status or histological type.
Results
Breast cancer-specific and relapse-free survival
In the survival analysis only the 100 patients with unilateral stage I-III disease were included. The same cut-off level of 0.5 was used because of a similar cyclin E distribution in these patients. The patients were followed for a median period of 53 months (23 -80 months) and divided into groups of 73 and 27 patients having tumours with low and high cyclin E levels respectively. Univariate analysis of breast cancer-specific survival showed that the group of patients with high tumour cyclin E levels experienced an increased risk (P=0.0002) of death owing to breast cancer compared with patients with tumours expressing low cyclin E levels (Figure 4) . By varying the cut-off value for the relative cyclin E concentration, statistical significance could be obtained in a broad interval of values (0.25-1.7). The high cyclin E level was moreover a risk factor in the subgroups of node-negative and node-positive patients (P=0.001 and 0.037 respectively).
Nodal status and oestrogen and progesterone receptor status Relative cyclin E concentration Figure 3 Oestrogen receptor concentrations vs relative cyclin E concentrations. Oestrogen receptor and relative cyclin E concentrations were truncated at values of 5 to get a clearer illustration.
were in addition found to be risk factors (Table II) . In univariate analysis of relapse-free survival the cyclin E level was found to be a significant risk factor for relapse 878 (P=0.015, Figure 5 ). The interval from diagnosis to relapse was shorter in the group of patients with high cyclin E levels compared with the group with low cyclin E (median 21 vs 37 months respectively, P=0.004), but no significant difference was found in the number of patients who experienced relapse in the two groups. Oestrogen receptor status and tumour size were additional risk factors for relapse (P= 0.008 and P=0.027 respectively, Table II ). In multivariate analysis of breast cancer-specific survival with covariates showing statistical significance in the univariate analysis, oestrogen receptor status and nodal status turned out to be independent prognostic factors (Table II) . Neither of the significant risk factors found in the univariate analysis of relapse-free survival was an independent risk factor in multivariate analysis (Table II) .
Discussion
Human cyclin E is a highly conserved protein that was first identified by virtue of its ability to rescue GI-cyclin-defective budding yeast (Koff et al., 1991) . It is a candidate protein for governing the progression of cells into S-phase because of several distinctive features: (1) the amount of cyclin E and cyclin E-cdk2 HI histone kinase activity increases during GI and peaks near the GI/S boundary; (2) it has a short half-life constituting the labile components that regulate the cdk2 kinase activity; (3) ectopic overexpression of the protein in fibroblasts shortens the GI interval; and (4) microinjection of antibodies against cyclin E in later part of GI blocks the entry into the S-phase (Draetta, 1994; Dou et al., 1993; Resnitzky et al., 1994) . In vivo substrates for the cyclin Ecdk2 kinase activity have not yet been fully determined but the complex might collaborate with cyclin D -cdk4 to phosphorylate and inactivate the retinoblastoma tumoursuppressor protein pRb, thereby releasing sequestrated transcription factors such as E2F that are important for the regulation of proteins implicated in the GI/S transition and the DNA synthesis (Weinberg, 1995). Overexpression of cyclin E has been observed in a variety of tumours, including breast cancer cell lines and tissue specimens, and given the central role for cyclin E in cell division, it has been suggested that this may contribute to the malignant phenotype, although no direct evidence exists that cyclin E is an oncogene (Buckley et al., 1993; Leach et al., 1993; Keyomarsi and Pardee, 1993; Keyomarsi et al., 1994; Dutta et al., 1995) . This overexpression seems to be tumour specific and not merely a secondary event caused by increased proliferation of tumour cells. In a study on breast cancer cell lines, ten of ten expressed high levels of cyclin E when compared with actively growing normal breast epithelial cells (Keyomarsi and Pardee, 1993) , and in another study using breast cancer tissue, no correlation was found between expression of cyclin E and that of proliferating cell nuclear antigen (PCNA), a marker of cell proliferation (Keyomarsi et al., 1994 Months after diagnosis Figure 4 Kaplan-Meier plot of breast cancer-specific survival in 100 patients with stage I-III disease.
Months after diagnosis Figure 5 Kaplan -Meier plot of breast cancer relapse-free survival in 100 patients with stage I-III disease. al., 1995) . However, a lack of correlation between the proliferative compartment and the amount of cyclin E-positive cells was also observed in several breast tumours suggesting that cyclin E is truly overexpressed in a group of breast tumours. The strong association between high cyclin E levels and receptor-negative tumours observed in this study also suggests a correlation between the cyclin E level and proliferation, since oestrogen receptor-negative tumours have repeatedly been shown to have a higher proliferation rate than receptor-positive tumours (Sigurdsson et al., 1990; Feichter et al., 1988; Meyer and Province, 1994) .
A remarkable result in the present study was the finding that a considerable part of oestrogen receptor-negative tumours expressed high cyclin E levels (22 of 33 tumours). The oestrogen receptor is a nuclear protein that functions as a transcription factor, regulating the expression of genes that constitute parts of a complicated network of molecules involved in control of cellular proliferation and differentiation in response to oestrogenic hormones. Several molecules in these pathways have been associated with increased tumorigenicity and the progress of breast cancer to a hormone-independent state (Horwitz, 1994; van Agthoven et al., 1992; Herman and Katzenellenbogen, 1994) . Our finding raises the possibility that overexpression of cyclin E could also be a potential operating mechanism to escape hormone dependence by promoting S-phase entry without the need for an oestrogenic stimulus. The mechanisms underlying cyclin E protein overexpression have not yet been defined in detail. The oestrogen receptor-negative breast cancer cell line MDA-MB-157 exhibits an 8-fold amplification of the cyclin E gene and a 64-fold overexpression of its mRNA that is translated into several overexpressed proteins (Buckley et al., 1993; Keyomarsi and Pardee, 1993) , but whether amplification of the cyclin E gene is a general event in breast cancer is unknown. Increased stability of mRNA has been reported (Keyomarsi and Pardee, 1993) , and alterations on the transcriptional level or upstream in the signal transducing pathways could be involved.
Of the oestrogen receptor-negative tumours, not all expressed high levels of cyclin E (11 of 33 tumours), and conversely, not all tumours showing high cyclin E levels were receptor negative (12 of 34 tumours), so the mechanisms leading to overexpression of cyclin E and the relationship to oestrogen receptor content may be complex and could involve other important cell cycle regulator molecules. In this context, cyclin DI is especially interesting, because experiments using breast cancer cell lines have shown that cyclin Dl expression is increased in response to mitogenicinduced cell proliferation Musgrove et al., 1993 Musgrove et al., , 1994 , and that the way anti-oestrogens block the cell cycle may involve down-regulation of cyclin Dl in GI (Watts et al., 1994) . Moreover, tumours exhibiting amplification of the region 1 q13 encompassing the cyclin Dl gene are often oestrogen receptor positive (Buckley et al., 1993; Musgrove et al., 1994; Adnane et al., 1989) , but the regulation of the cyclin Dl gene and its role in oestrogennegative tumours has yet to be defined. Differential deregulation of several crucial cell cycle control molecules could possibly be implicated in hormone-independent breast cancer and may explain why a minor group of oestrogen receptor-negative patients in our study apparently had low cyclin E expression.
In summary, we have demonstrated large variations in cyclin E protein expression among tumours from patients with primary breast cancer, identified cyclin E as a new prognostic factor and could show a strong relationship between cyclin E protein abundance and oestrogen receptor-negative status, pointing to a possible role for cyclin E in the mechanisms responsible for oestrogen hormone-independent tumour growth. In our laboratory we currently study the pattern of expression of several important cell cycle regulators in oestrogen-positive and -negative tumours in the hope of getting a more coherent picture of the observed variations in cyclin expression and oestrogen receptor status, which in the future could possibly be applied to classify breast cancer according to the prevailing mechanisms of cell cycle deregulation.
